pramttl's comments

Tabnine is my personal favorite as it works with most IDEs including IntelliJ, Vim and even VSCode and the suggestions are high-quality. I actually moved away from Copilot to Tabnine across all IDEs and haven't gone back since.

I can see how some people see this as positive but the premise that a talented and hard working foreign worker takes a job away from a citizen is short-sighted. Zoom out a little and instead of a talented and hardworking foreign employee taking a job you will see (on an average) that they help grow or expand projects and companies that opens door to hiring more people. Not only do they pay tax here and support social security benefits that many enjoy, they also help businesses survive and grow and help them stay competitive in a global market.

I'm not calling for open doors to everyone, this certainly needs a balanced approach. However, with such suspensions I think we seem to be going one extreme path. Global talent has helped develop industries and businesses here. Increasing restrictions to this extent and suspending these visas is going to push this talent out and promising businesses who want to get the best talent to work with them, will not-immediately but definitely follow their way out too. I hope the people who are celebrating this, at-least for a few minutes, come out of the myopic view and look at the long term economic consequences.

Great tool, would be nice to also have a chrome extension for the same that augments dev-tools to reduce one extra step of copy/paste.

Beautiful explanation for something that tripped me up in early days of using mock/patch. Summary: (1) Variables in Python are names that refer to values. (2) (For that reason) Mock an object where it is used, not where it is defined.

A talented (foreign) friend of mine had the opportunity to switch to a better, higher paid role but due to the effort involved, the risk and the pause in H1B premium processing just hung on to his current role.

The H1B program itself is not a problem and in-fact is a big positive contributor to the US economy; but it definitely has issues like the one you highlighted (e.g. harder for employees to switch jobs) that should be addressed by the government to make it more viable.

GoodRx is not a Pharmacy Benefit Manager (PBM) actually. A PBM negotiates prices with pharmacies to include them in their network, GoodRx does not do that to my knowledge. Instead, GoodRx offers a service that allows users to compare different coupon and membership prices so that people can chose the best available price/pharmacy combination.

GoodRx is strictly against selling personal medical data. Reference. https://support.goodrx.com/hc/en-us/articles/115005228506-Pr...

"GoodRx does not sell information regarding your drug prescriptions and medical conditions that are linked to your name, contact information and other personal data you provide us."

The only people who would have solved the captcha faucet to get coins at virtually next to nothing value at that time would be the ones who believed in the project right from the start which to me is a fair distribution scheme. ICO based distribution is usually more greed driven. In this case the developers and team were more motivated in building a new innovative blockchain protocol as opposed to raising money by simply issuing ERC20 tokens. Speaks a lot about the project in itself. And the team has even succeeded in building a beautiful, disruptive scalable protocol and currency with no transaction fee. I've tried RaiBlocks and so far have been impressed.

I always wondered why do we have to pay for domain names annually. Now I understand where that money actually goes. There are 340+ million registered domain names. [1] Annual ICANN subscription price of a domain name is about 10$. That is a guaranteed annual revenue of 3.4bn USD and consistently growing and no one can give ICANN a competition because effectively it's a monopoly. That is a lot of money for a "non-profit". We have reached a serverless computing era where paying for compute/storage for a small service is becoming cheaper than owning a domain name and the price for "buying" domains hasn't changed in years. People are so used to the standard domain pricing that they are willing to pay that subscription amount. All of this while executives of a non-profit get filthy rich. Me feeling unfair about it is not enough to change the market, but I sure do derive some business learning from this.

[1] https://investor.verisign.com/releasedetail.cfm?releaseid=98...

You can still use the old way of using <script src=..>. See index.html in the following plunkr (sample angular app): http://embed.plnkr.co/xTyGA7Klq8Mta2T1yANh/

I have found Angular CLI productive, because it helps quickly generate components (each component has an html, ts, css, and spec.ts file with some boilerplate code). It is fairly quick to get up and running with angular-cli as compared to writing a webpack configuration file. However, since angular-cli is in beta, it lacks the flexibility that using webpack directly would offer. (P.S: Angular-CLI latest release would be using webpack internally)

I didn't have to migrate tests over since I was started with a fresh project in Angular 2.

Angular Router does allow nested states: - https://angular.io/docs/ts/latest/guide/router.html - https://angular.io/docs/ts/latest/api/router/index/Router-cl...

I don't quite recall what "targetted views" mean?

I have been using Angular 2 for 3 months now and so far have loved it (except for the breaking changes in RC series and updating each time). Glad 2.0.0 is here. Here are the few things I loved, amongst other interesting features:

1. Typescript awesomeness: You can write plain JS or give type hints in Typescript. Typescript is awesome, because it is a superset of Javascript and compiles to Javascript. (Typescript > ES6 > ES5)

2. Modular code: It is is much easier to manage Angular code as it grows (compared to AngularJS). Components could be made independently and reused within other components using component interaction [1] (@Input, @Output)

3. Template Directives: .html template directives are available unlike ReactJS. A ReactJS vs Angular2 blog post online [1] argued that that putting HTML in Javascript is better than putting Javascript in HTML. I'd argue that template directives like ngFor, ngIf, etc are much simpler to understand. Also, it is easier to collaborate with a designer/half-developer who knows some html/scss and doesn't know Javascript than working in ReactJS where every collaborator has to know JS. This way, it is also easier for someone to gradually learn the framework. For me, template directives are a big win. If someone wants to construct templates with plain JS, that is still possible in Angular.

4. @angular/router is better than AngularJS routing and we don't have to use a 3rd party library (like ui-router was more popular in AngularJS than the angularjs router)

One thing that I have found annoying is that: UI libraries for Angular. Example: material2 (currently at alpha.8) [3] are not complete yet and lack several useful components. This can be a problem if you are looking to quickly build a complete, good looking UI. Hopefully, now with Angular 2.0.0 out; Angular team could focus on quicker development of material2, so we have all the AngularJS Material UI goodness with Angular.

[1] https://angular.io/docs/ts/latest/cookbook/component-communi... [2] https://medium.freecodecamp.com/angular-2-versus-react-there... [3] https://github.com/angular/material2

Since we are yet to see the first Angular2 release (almost there, but not yet); most Angular2 third-party resources may not provide the most up to date information, so the best place to learn Angular right now is really the official Angular documentation i.e. https://angular.io/ , because it is updated quite often.

1. If you are looking for a book to learn in a sequential way then ng-book is a good option. ng-book is updated regularly however it is not free. https://www.ng-book.com/2/#features

2. New blog posts are also a great way to learn about certain Angular topics. Examples:

2(a): http://blog.thoughtram.io/categories/angular-2/

2(b): http://angularjs.blogspot.com/ (Has both Angular 1.x and 2.x articles, written by Angular core developers)

3. Learning by observing:

3(a): material2 is a library, being developed by the Angular team itself, that is based on Angular2 and is frequently updated to use the latest Angular2 version (currently RC5). I refer to the material2 source code to learn the best way to write my own Angular2 app and custom components: https://github.com/angular/material2/tree/master/src/lib

Do you see new OPT STEM extension (24 months) and it's requirements be something that could be met by most F-1 student entrepreneurs on OPT?

Background: The new 24 month STEM OPT Extension [1] (effective from May 10, 2016) which requires employers to fill I-983 [2] (Lengthy Training Plan) has created additional barrier for foreign students intending to start/work with startup companies on STEM OPT Extension (which earlier was for 17 months with less regulations). Being an F-1 student myself I can say that, these regulations could certainly influence more potential F-1 entrepreneurs down the "job seeking" path as opposed to "job creation/entrepreneurship" path because it is much easier for bigger companies with resources to satisfy the USCIS training plan requirements/I-983 as opposed to newly born companies.

[1] https://www.uscis.gov/working-united-states/students-and-exc...

[2] https://www.ice.gov/sites/default/files/documents/Document/2...

I was once prescribed 4 tablets of Albandazole (a drug for worms treatment) just before my health insurance was active on file. The drug was costing over 700$ without insurance and my health center asked if I would like to wait for my student health insurance to show up as active. I said, yes (ofcourse) shocked at the price of the drug (being an international student in US from India). Even after my insurance I paid 35$ co-pay. The same drug costs <1$ in India. Even the co-pay is over 35 times the cost of the drug in India. I was trying to contrast some figures:

Salary ratio: ~5:1 (Software engineer, Google based on Glassdoor); Albendazole drug cost ratio: ~700:1